CD56-positive haematological neoplasms of the skin: A multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer

VU University Amsterdam, Amsterdamo, North Holland, Netherlands
Journal of Clinical Pathology (Impact Factor: 2.92). 10/2007; 60(9):981-9. DOI: 10.1136/jcp.2006.042135
Source: PubMed


Cutaneous lymphomas expressing CD56, a neural cell adhesion molecule, are characterised in most cases by a highly aggressive clinical course and a poor prognosis. However, prognostic subsets within the CD56+ group have been difficult to identify due to the lack of uniform clinicopathological and immunophenotypical criteria.
A multicentre study was conducted by the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer to define prognostic parameters and establish diagnostic and therapeutic guidelines for CD56+ haematological neoplasms presenting primarily in the skin.
Four different subtypes of lymphoproliferations with CD56 expression were identified: (1) haematodermic neoplasm; (2) skin infiltration as the first manifestation of CD56+ acute myeloid leukaemia; (3) nasal-type extranodal natural killer/T-cell lymphoma; and (4) "classical" cases of cutaneous T-cell lymphoma (CTCL) with co-expression of the CD56 molecule. Patients in the first three groups had a poor outcome (93% died) with a median survival rate of 11 months (95% CI 2-72 months), whereas all patients with CD56+ CTCL were alive at the last follow-up.
Results show that CD56+ cutaneous lymphoproliferative disorders, with the exception of CD56+ CTCL have a very poor prognosis. It is therefore clinically important to separate CD56+ CTCL from the remaining CD56+ haematological disorders.

Download full-text


Available from: Alistair Robson,

Click to see the full-text of:

Article: CD56-positive haematological neoplasms of the skin: A multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer

5.16 MB

See full-text
  • Source
    • "A broad immunohistochemical panel is needed to distinguish this neoplasm from myeloid sarcoma and should include lysozyme and myeloperoxidase, which are not expressed in BPDCN. CD33 is also typically not expressed, while immunohistochemistry for CD123 and CD43 are uniformly positive (Petrella et al., 2005; Assaf et al., 2007). Unfortunately, variable CD123 expression has been noted in AML (Sano et al., 2008), and as stated earlier, CD43 expression is nonspecific. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myeloid sarcomas are extramedullary lesions composed of myeloid lineage blasts that typically form tumorous masses and may precede, follow, or occur in the absence of systemic acute myeloid leukemia. They most commonly involve the skin and soft tissues, lymph nodes, and gastrointestinal tract and are particularly challenging to diagnose in patients without an antecedent history of acute myeloid leukemia. We conducted a search of the English language medical literature for recent studies of interest to individuals involved in the diagnosis of myeloid sarcoma. The differential diagnosis includes non-Hodgkin lymphoma, blastic plasmacytoid dendritic cell neoplasm, histiocytic sarcoma, melanoma, carcinoma, and (in children) small round blue cell tumors. The sensitivity and specificity of immunohistochemical markers must be considered when evaluating a suspected case of myeloid sarcoma. A high percentage of tested cases have cytogenetic abnormalities. A minimal panel of immunohistochemical markers should include anti-CD43 or anti-lysozyme as a lack of immunoreactivity for either of these sensitive markers would be inconsistent with a diagnosis of myeloid sarcoma. Use of more specific markers of myeloid disease, such as CD33, myeloperoxidase, CD34 and CD117 is necessary to establish the diagnosis. Other antibodies may be added depending on the differential diagnosis. Identification of acute myeloid leukemia-associated genetic lesions may be helpful in arriving at the correct diagnosis.
    International journal of laboratory hematology 08/2011; 33(6):555-65. DOI:10.1111/j.1751-553X.2011.01361.x · 1.82 Impact Factor
  • Source
    • "Several authors have advocated the establishment of a prognostic model for NK/T cell lymphoma nasal type that is more reliable than IPI1,7,17,18 (International Prognostic Index). Factors significantly associated with a worse prognosis are male gender, the presence of B-symptoms, high LDH, advanced stage and CD30 negativity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since nasal NK/T cell lymphoma and NK/T cell lymphoma nasal type are rare diseases, gastric involvement has seldom been seen. We report a unique case of a patient with a primary NK/T cell lymphoma nasal type of the stomach with skin involvement. The patient had no history of malignant diseases and was diagnosed with hematemesis and intense bleeding from his gastric primary site. Shortly after this event, exanthemic skin lesions appeared with concordant histology to the primary site. Despite chemotherapy, the patient died one month after the first symptomatic appearance of disease.
    Rare tumors 12/2009; 1(2):e58. DOI:10.4081/rt.2009.e58
  • Source
    • "Certain hematopoietic neoplasms have a tendency to involve the skin. Of these the most common are CD4+/CD56+ hematodermic neoplasms (previously termed blastic natural killer (NK) cell lymphoma), myeloid sarcomas, nasal-type extranodal natural killer/T-cell lym-phoma, and cutaneous T-cell lymphomas.1 The term myeloid sarcoma refers to tumors composed of aggregates of immature leukemic myeloid precursors in extramedullary sites.2 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myeloid sarcomas are tumor masses composed of aggregates of malignant myeloid precursors in extramedullary sites including the skin. We report a case of myeloid sarcoma in a patient who presented with an ear lobe mass and facial nerve paralysis. Expression of CD56 by the malignant cells led to an initial misdiagnosis as Merkel cell tumor. Comprehensive pathological evaluation confirmed the diagnosis of myeloid sarcoma with aberrant expression of CD56 and carrying the translocation t(8;21) (q22;q22). Aberrant antigen expression by cutaneous myeloid sarcomas can cause diagnostic confusion with other cutaneous neoplasms. This is especially relevant when myeloid sarcoma is the sole manifestation of acute myeloid leukemia.
    Rare tumors 12/2009; 1(2):e51. DOI:10.4081/rt.2009.e51
Show more